Creo Medical Group PLC Director/PDMR Share Dealings
21 October 2024 - 8:06PM
RNS Regulatory News
RNS Number : 9613I
Creo Medical Group PLC
21 October 2024
LEI: 213800H188ZDCWWXFA21
21 October 2024
Creo Medical Group
plc
("Creo"
or the "Company")
Director/PDMR Share
Dealings
Further to the announcements made on
30 September 2024 and 18 October 2024, and pursuant to the recent
fundraising, the Company confirms that the following directors of
the Company have acquired New Ordinary Shares at the Issue Price of
24 pence per Ordinary Share as follows:
|
Director/PDMR Name
|
No.
of New Ordinary Shares Acquired
|
Resultant Shareholding post transaction
|
%
of voting rights post transaction
|
|
Kevin Crofton
|
2,916,666
|
3,566,666
|
0.87%
|
|
Richard Rees
|
208,333
|
3,036,540
|
0.74%
|
|
Creo Medical
Group plc
|
www.creomedical.com
|
|
Richard Craven, Company Secretary
|
Via Walbrook
PR
|
|
|
|
|
Cavendish
Capital Markets Limited
(Nominated
Adviser, Joint Bookrunner and Joint Broker)
|
+44 (0)20 7220
0500
|
|
Stephen Keys / Camilla Hume / George Lawson
(NOMAD)
|
|
|
Michael Johnson (Sales)
|
|
|
|
|
|
Deutsche Numis
(Joint Bookrunner and Joint Broker)
Freddie Barnfield / Duncan Monteith / Euan
Brown
William Baunton (ECM)
|
+44 (0)20
7260 1000
|
|
|
|
|
Walbrook PR
Ltd
|
Tel: +44 (0)20 7933
8780 or creo@walbrookpr.com
|
|
Paul McManus / Phillip Marriage
|
Mob: +44 (0)7980 541
893 / +44 (0)7867 984 082
|
|
|
|
|
|
NOTIFICATION
AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH
THEM
|
1
|
Details of the
person discharging managerial responsibilities / person closely
associated
|
|
a)
|
Name
|
Kevin Crofton
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Non-Executive Chairman
|
|
b)
|
Initial notification/Amendment
|
Initial Notification
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Creo Medical Group plc
|
|
b)
|
LEI
|
213800H188ZDCWWXFA21
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
|
Ordinary shares of £0.001 each
|
|
|
Identification code
|
GB00BZ1BLL44
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volumes(s)
|
Price(s)
|
Volume(s)
|
|
£0.24
|
2,916,666
|
|
d)
|
Aggregated information
|
N/A single transaction
|
|
|
Aggregated volume
|
N/A single transaction
|
|
|
Price
|
N/A single transaction
|
|
e)
|
Date of the transaction
|
21 October 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1
|
Details of the
person discharging managerial responsibilities / person closely
associated
|
|
a)
|
Name
|
Richard Rees
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial notification/Amendment
|
Initial Notification
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Creo Medical Group plc
|
|
b)
|
LEI
|
213800H188ZDCWWXFA21
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
|
Ordinary shares of £0.001 each
|
|
|
Identification code
|
GB00BZ1BLL44
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volumes(s)
|
Price(s)
|
Volume(s)
|
|
£0.24
|
208,333
|
|
d)
|
Aggregated information
|
N/A single transaction
|
|
|
Aggregated volume
|
N/A single transaction
|
|
|
Price
|
N/A single transaction
|
|
e)
|
Date of the transaction
|
21 October 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHGCBDGUGDDGSB
Creo Medical (LSE:CREO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From Nov 2023 to Nov 2024
